Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853994 | 0.98 | GAA (0.46) | GAATDP1CES2ALDH1A1MAPT | |
| SCHEMBL855206 | 0.98 | GAA (0.46) | GAATDP1CES2ALDH1A1MAPT | |
| SCHEMBL5234963 | 0.85 | GAA (0.40) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL854998 | 0.83 | GAA (0.39) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL853966 | 0.83 | GAA (0.36) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL4859801 | 0.80 | TDP1 (0.37) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL31327082 | 0.74 | GAA (0.38) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL7400810 | 0.71 | ALDH1A1 (0.36) | GAACES2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16050086 | 0.67 | GAA (0.49) | GAATDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL24517944 | 0.67 | CES2 (0.35) | CES2ALDH1A1KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2021-08-17 | — | — | US | disclosed |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-24 | — | — | US | disclosed |
| EP-2970138-B1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2019-01-16 | — | — | EP | disclosed |
| EP-2970138-B1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2019-01-16 | — | — | EP | disclosed |
| US-10130609-B2 | Pyrazole derivatives and their uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2016-01-28 | — | — | US | disclosed |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2016-01-28 | — | — | US | disclosed |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2016-01-28 | — | — | US | disclosed |
| EP-2970138-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | Canadian Blood Services (CA) | 2016-01-20 | — | — | EP | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130609-B2 | Pyrazole derivatives and their uses thereof | SSB, HLA-DRB1, U2AF1 | GAA 3034/4885TDP1 708/4885CES2 4121/4885 |
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | SSB, HLA-DRB1, U2AF1 | GAA 3393/4885TDP1 862/4885CES2 4226/4885 |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | SSB, HLA-DRB1, U2AF1 | GAA 3034/4885TDP1 708/4885CES2 4121/4885 |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | SSB, HLA-DRB1, U2AF1 | GAA 3393/4885TDP1 862/4885CES2 4226/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | GAA 3005/4885TDP1 811/4885CES2 1069/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | GAA 2942/4885TDP1 1243/4885CES2 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.